The New Jersey, US-based Johnson & Johnson (NYSE:JNJ) have decided to change court after a series of rulings have gone against the company, forcing them to pay close to $200 million compensation. The plaintiffs have charged that Johnson & Johnson products, particularly their talcum powder cause ovarian cancer.
Johnson & Johnson Loses Three Cases in the Same Court
On October 27, Johnson & Johnson lost a case over their talcum powder link with cancer at a court in St. Louis, US, and had to pay a compensation of $70 million to a woman. The talcum powder supplier was also fined by the court.
This was their third straight trial loss in the same court. Together, the compensation the company had to give totals a staggering $195 million. Though the latest case was decided by a jury, but it was the same judge all three times.
But that is not all. There are many other pending lawsuits against the business. In fact, at this time, there are 2,500 pending similar cases, most of them in the same court in St. Louis. The plaintiffs are claiming that their talcum powder causes ovarian cancer. Reports of studies have been forwarded to support the claim.
Johnson & Johnson Unhappy With the Rulings
Johnson & Johnson, on the other hand, questions the findings of these studies. The business has also submitted its own reports, claiming that more comprehensive studies have not shown any direct link. Now by changing the court, Johnson & Johnson is hoping that the fate of the other trials will be different.
Johnson & Johnson (NYSE:JNJ) now says that most jury members are from St. Louis, and the business does not have strong ties in the area. So the company does not want the cases to be heard there. In fact, this argument was raised by the business in the court during the latest trial. But the judge turned it down.
Johnson & Johnson wants to raise the same point again. John Beisner, a top lawyer representing the business says that we will refill elsewhere if the court rejects this again.
Incidentally, a judge in New Jersey had ruled in favor of Johnson & Johnson in September, saying that the scientific testimony presented by the plaintiffs was “too speculative”. The business is based in New Jersey and naturally has more influence there. Two other cases have also been dismissed in the court in New Jersey.